Ambit Biosciences Corp (AMBI) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
11080 ROSELLE STREET SAN DIEGO, CA 92121 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 6/30/2014 MRQ | 12/31/2013 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 71,189,000 | |||
| Cash and cash equivalents | 71,189,000 | |||
| Receivables | 1,000,000 | |||
| Other undisclosed current assets | 911,000 | |||
| Total current assets: | 73,100,000 | |||
| Noncurrent Assets | ||||
| Property, plant and equipment | 785,000 | |||
| Restricted cash and investments | 63,000 | |||
| Total noncurrent assets: | 848,000 | |||
| TOTAL ASSETS: | 73,948,000 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 9,557,000 | |||
| Employee-related liabilities | 1,997,000 | |||
| Accounts payable | 1,516,000 | |||
| Accounts payable and other accrued liabilities | 4,711,000 | |||
| Accrued liabilities | 1,333,000 | |||
| Other undisclosed current liabilities | 6,801,000 | |||
| Total current liabilities: | 16,358,000 | |||
| Noncurrent Liabilities | ||||
| Total liabilities: | 16,358,000 | |||
| Equity | ||||
| Equity, attributable to parent | 57,590,000 | |||
| Common stock | 18,000 | |||
| Additional paid in capital | 306,064,000 | |||
| Accumulated other comprehensive loss | (326,000) | |||
| Accumulated deficit | (248,166,000) | |||
| Total equity: | 57,590,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 73,948,000 | |||
Income Statement (P&L) (USD)
| 6/30/2014 TTM | 12/31/2013 | ||
|---|---|---|---|
| Operating expenses | (34,126,000) | ||
| Other undisclosed operating income | 27,093,000 | ||
| Operating loss: | (7,033,000) | ||
| Nonoperating expense | (4,252,000) | ||
| Interest and debt expense | (323,000) | ||
| Loss from continuing operations before equity method investments, income taxes: | (11,608,000) | ||
| Other undisclosed income from continuing operations before income taxes | 323,000 | ||
| Loss from continuing operations before income taxes: | (11,285,000) | ||
| Income tax benefit | 29,000 | ||
| Loss from continuing operations: | (11,256,000) | ||
| Loss before gain (loss) on sale of properties: | (11,256,000) | ||
| Net loss: | (11,256,000) | ||
| Net income attributable to noncontrolling interest | 61,000 | ||
| Net loss attributable to parent: | (11,195,000) | ||
| Preferred stock dividends and other adjustments | (3,634,000) | ||
| Other undisclosed net income available to common stockholders, basic | 1,747,000 | ||
| Net loss available to common stockholders, diluted: | (13,082,000) | ||
Comprehensive Income (USD)
| 6/30/2014 TTM | 12/31/2013 | ||
|---|---|---|---|
| Net loss: | (11,256,000) | ||
| Other undisclosed comprehensive loss | (373,000) | ||
| Comprehensive loss, net of tax, attributable to parent: | (11,629,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.